Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on February 23, 2017. The filing reports financial results for the quarter and full year ended December 31, 2016.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not disclose specific material changes versus prior periods. It only confirms that results for the reported period have been issued.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the information furnished, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) in Exhibit 99.1 (Press Release dated February 23, 2017).
- Confirm the company name is Obalon Therapeutics, Inc. and not Vyome Holdings, Inc.
- Review the full press release for any forward-looking statements or operational updates not summarized in this 8-K.
- Check subsequent filings for the incorporation of this data into formal 10-Q or 10-K reports.